Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

484 results about "Erythroid cell" patented technology

Erythroid Cells. Erythroid Cells are also called erythrocytes. These are the most common type of blood cell and the vertebrate organism's principal means of delivering oxygen to the body tissues via blood flow through the circulatory system.

Hemodialysis on-line monitoring system and method

InactiveCN120242208ADialysis systemsSensorsSerum ironErythroid cell
The invention relates to the technical field of hemodialysis monitoring, and provides a hemodialysis on-line monitoring system and method, and the system comprises a data acquisition module which is used for collecting blood physiological parameters in a dialysis pipeline in real time; the blood component analysis module is connected with a blood loop of the dialysis machine and is used for detecting serum iron, ferritin and ferritin saturation indexes on line; and the data processing module is used for calculating the risk index of anemia, evaluating the iron utilization rate, constructing a model for measuring the iron deficiency erythropoiesis trend according to the collected and analyzed data, and training and optimizing the model. According to the method, individual parameters of patients are fused, personalized calculation is performed for iron metabolism rates and dialysis parameters of different patients, and data such as iron content, blood flow and dialysis fluid volume are acquired online in real time, so that iron concentration and infusion rate are accurately matched with real-time iron metabolism requirements of the patients, and anemia of the patients in the dialysis process is reduced.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE

Hydrogel with photo-thermal multiple antibacterial and hemostatic functions as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to hydrogel with photo-thermal multiple antibacterial and hemostatic functions. The multifunctional hydrogel is prepared from epsilon-polylysine (EPL), gallic acid (GA), tannic acid (TA) and ferric trichloride hexahydrate. The polyphenols are obtained through multiple mechanisms such as reaction between the polyphenols and amino groups, metal chelation, pi-pi interaction and electrostatic attraction (as shown in Figure 1). The metal ion and multiple dynamic cross-linking system hydrogel is constructed, the hydrogel with positive charges enriched on the surface can act with blood platelets with negative charges, red blood cell aggregation, blood platelet adhesion and vasoconstriction effects are promoted, and the blood coagulation efficiency is improved. The hydrogel shows excellent antibacterial performance and photo-thermal performance, can prevent infection in the inflammation stage of wound healing, can effectively accelerate wound healing, and has good biological safety.
Owner:JILIN INST OF CHEM TECH

Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

PendingUS20250228827A1Organic active ingredientsMetabolism disorderCongenital erythropoietic porphyriaPharmaceutical drug
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and / or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Owner:DISC MEDICINE INC

Precise medication system for hemodialysis patient based on multiple omics and big data

The invention relates to the technical field of medical care informatics and precision medical treatment, and discloses a hemodialysis patient precision medication system based on multiple omics and big data, and the system comprises a multi-source data collection module which collects the multi-source heterogeneous data of a patient and carries out the standardization and integration processing; the drug metabolism analysis module is used for analyzing drug metabolism paths and individual differences through multi-omics data, constructing a drug metabolism polymorphic model and outputting gene metabolism capability grades and biomarker risk tags; the initial medication decision-making module is used for constructing an initial medication decision-making model based on a federal optimization framework of a momentum enhancement and robust aggregation mechanism, and outputting a personalized initial medication scheme for erythropoietin and a vein iron agent; and the drug dosage adjustment module is used for dynamically optimizing the time node and dosage adjustment opportunity of drug administration through an asynchronous federal reinforcement learning framework in combination with a prospective parameter correction strategy. According to the invention, the intelligent medication system with strong robustness and fine decision is constructed.
Owner:YUQING HEMODIALYSIS SERVICE MANAGEMENT GRP CO LTD

Application of compound DB07268 in preparation of RAGAP1 inhibitor

The invention relates to an application of a compound DB07268 in preparation of a RAGAP1 inhibitor. Candidate compounds possibly interacting with RACGAP1 protein are screened out through large-scale virtual docking and CCK8 experiments and verified through SPR experiments, the compound DB07268 with the highest affinity with RACGAP1 is further screened out, and finally the acting effect of the compound DB07268 is verified through cell experiments and molecular experiments. Compared with the prior art, the invention discovers that DB07268 can be used as the RACGAP1 inhibitor for targeted therapy of RACGAP1 related diseases, such as various tumors, diabetic nephropathy, acute kidney injury, congenital heart disease, congenital erythropoiesis abnormality anemia, virus infectious diseases and the like.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Aurone compound and medical application thereof

The invention provides an aurone compound and medical application thereof, and relates to an aurone compound and application thereof in preparation of drugs for preventing and treating myelosuppression or blood system diseases. The aurone compound provided by the invention can significantly improve the myelosuppression state caused by rusotinib and radiotherapy, can recover the generation of erythrocytes after mouse irradiation and use of rusotinib, and has a significant effect on the recovery of leukocytes, especially neutrophils and lymphocytes, of the irradiated mouse. The invention provides a new potential drug for treatment of myelosuppression or blood system diseases.
Owner:ZHEJIANG UNIV +1

Compositions and methods for med26-mediated regulation of erythropoiesis

PCT designated stage expiredWO2024255872A1Peptide/protein ingredientsGenetically modified cellsErythrocyte differentiationMED26
Provided are methods and agents for promoting erythroid differentiation. Also provided are methods of increasing RNA polymerase II pausing mediated by a MED26 polypeptide. Also provided are methods of delivering a reagent to a cell.
Owner:PEKING UNIV +1

Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

PendingUS20240390362A1Organic active ingredientsMetabolism disorderCongenital erythropoietic porphyriaBitopertin
The present embodiments are directed to methods of using a crystalline form (such as form A, B, or C, or a methylparaben cocrystal form) or an amorphous form of Bitopertin, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and / or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Owner:DISC MEDICINE INC

Serum-free feeder-layer-free method for efficiently inducing directional differentiation and maturation of human hematopoietic stem cell erythroid

The invention relates to a method for efficiently inducing human hematopoietic stem progenitor cell erythroid to be directionally differentiated into mature erythrocytes in a serum-free and feeder-layer-free manner, which adopts a serum-free and feeder-layer-cell-free induction culture system, and uses an mTOR pathway inhibitor rapamycin to regulate the activity of an mTOR pathway in the erythroid differentiation process. The use dosage and the treatment mode of the mTOR pathway inhibitor rapamycin are further optimized, and the erythrocyte denucleation efficiency of an in-vitro induced differentiation system is remarkably improved to 70% under the condition that erythrocyte proliferation and differentiation are not affected or the cell state is not reduced. According to the method, heterologous pollution caused by animal serum or heterologous cells is effectively avoided, the clinical safety of in-vitro preparation of transfusion-level red blood cells in the future is ensured, the erythroid directional induced differentiation final maturation efficiency of the human hematopoietic stem progenitor cells is improved, meanwhile, the reagent cost is reduced, and large-scale preparation and clinical transformation are facilitated.
Owner:THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIV MEDICAL COLLEGE

Constitutive cytokine receptors

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.
Owner:GUELL MEDICAL LTD

Application of qi and blood foundation strengthening oral liquid in preparation of body building and anti-aging medicine

The invention provides application of qi-blood foundation strengthening oral liquid in preparation of a medicine for building body and resisting aging, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by adopting the modes of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood not only has the effective component content, but also has the health-care effect. The oral liquid for consolidating qi and blood has the effects of improving the activity of superoxide dismutase of red blood cells and reducing the content of lipofuscin in tissues, can improve the exercise tolerance of rats, and has the effects of resisting aging and building the body.
Owner:内蒙古长寿药业有限公司

Methods of treating anemia using salmeterol or a pharmaceutically acceptable salt thereof

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.
Owner:DANA FARBER CANCER INSTITUTE INC

Artificial blood vessel and preparation method thereof

The invention discloses an artificial blood vessel and a preparation method thereof, and the preparation method comprises the following steps: uniformly mixing an erythrocyte ghost suspension and melanin nanoparticles to obtain a mixed solution; carrying out ultrasonic treatment and extrusion on the mixed solution to obtain a melanin nano-vesicle solution; carrying out electrostatic spinning on the polycaprolactone solution to obtain a polycaprolactone electrostatic spinning blood vessel; soaking the polycaprolactone electrostatic spinning blood vessel in an ethylenediamine solution, and then washing the polycaprolactone electrostatic spinning blood vessel with a phosphate buffer solution; then soaking in a 4-morpholine ethanesulfonic acid solution; finally, carrying out heparinization in a 4-morpholine ethanesulfonic acid solution containing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and heparin; and incubating the heparin-modified polycaprolactone electrostatic spinning blood vessel in the melanin nano-vesicle solution to obtain the artificial blood vessel. The melanin nano-vesicles are modified, so that the anticoagulation performance of erythrocyte membranes is reserved, and meanwhile, the scavenging capacity of melanin nano-particles on reactive oxygen free radicals is reserved.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Methods of modulating erythropoiesis using beta-2 adrenergic receptor antagonists

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.
Owner:DANA FARBER CANCER INSTITUTE INC

Application of colla corii asini bone-strengthening oral liquid in preventing and / or treating anemia

PendingCN119792413AMetabolism disorderPharmaceutical delivery mechanismUrea nitrogen/CreatinineSerum iron
The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.
Owner:XINJIANG HUASHIDAN PHARMA

Genetically modified non-human animals expressing human EPO

The present invention relates to genetically modified non-human animals expressing human EPO. Genetically modified non-human animals expressing human EPO from animal genomes are provided. Also provided are methods for generating non-human animals expressing human EPO from non-human animal genomes, and methods for using non-human animals expressing human EPO from non-human animal genomes. These animals and methods have many uses in the art, including, for example, modeling of human erythropoiesis and erythrocyte function; modeling of human pathogen infection of erythrocytes; in vivo screening of agents regulating erythropoiesis and / or erythrocyte function, for example in a healthy or diseased state; screening of agents toxic to erythrocytes or erythrocyte progenitors; in vivo screening of agents that prevent, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in vivo screening of erythrocytes or erythrocyte progenitors from individuals to predict individual responsiveness to disease therapy.
Owner:REGENERON PHARMACEUTICALS INC +2

Application of GDF15 in preparation of medicine for treating DON poisoning and medicine thereof

PendingCN119386165AInhibit proliferation and differentiationGrowth inhibitionPeptide/protein ingredientsAntinoxious agentsMature erythrocyteReticulocyte count decreased
The invention provides application of GDF15 in preparation of a medicine for treating or preventing hematopoietic dysfunction caused by DON poisoning. The research finds that the GDF15 has the effects of treating or preventing bone marrow total cell reduction, hematopoietic stem progenitor cell damage, erythroid progenitor cell damage, erythroid end developmental stage damage, reticulocyte number reduction and peripheral blood mature erythrocyte damage caused by DON poisoning, and the exogenous GDF15 can relieve inhibition of DON poisoning on cell growth and development through research. And a GDF15-beta-catenin-Myc signal channel is activated, so that the downstream Myc, p27 and p21 are normally expressed. The invention discloses a new application of GDF15 in treatment of DON poisoning.
Owner:ZHENGZHOU UNIV

Lineage specification during stem cell transition

A method of generating a hematopoietic cell, including providing a source cell and treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation and / or cholesterol biosynthesis, wherein the source cell is differentiated into a GPA+ erythroid cell or a CD45+ non-erythroid cell. In some examples, the source cell is selected from the group consisting of a hemogenic endothelial (HE) cell, a iPS cell such as a differentiating iPS cell, a cell directly reprogrammed to a known pre-cursor of a hematopoietic cell, a cell directly reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, a reprogrammed cell that is subsequently further reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, an adult hematopoietic cell derived from bone marrow or mobilized peripheral blood and a neonatal hematopoietic cell derived from cord blood or prenatal tissue (e.g. placenta). Some examples involve metabolically regulating a lipid biosynthesis pathway with an inhibitor of the lipid biosynthesis pathway or metabolically regulating a histone acetylation pathway with an inhibitor of the histone acetylation pathway.
Owner:MAGLE CHEMOSWED HOLDING AB

Composite antibody immunomagnetic bead as well as preparation method and application thereof

The invention discloses a composite antibody immunomagnetic bead and a preparation method and application thereof, and the preparation method comprises the following steps: (1) cleaning a magnetic bead, and activating the magnetic bead with an activator; (2) adding a composite anti-erythrocyte antibody into the activated product obtained in the step (1) for antibody coupling; the composite anti-erythrocyte antibody at least comprises two anti-erythrocyte antibodies with different epitopes; (3) adding a magnetic bead sealing agent into the antibody coupling product obtained in the step (2) for sealing, and performing strong magnetic separation after the reaction is finished; and (4) adding a product obtained after strong magnetic separation in the step (3) into a freeze-drying buffer solution, uniformly dispersing, sub-packaging, adding a free red blood cell antibody, and performing vacuum freeze-drying to obtain the composite antibody immunomagnetic beads. The composite antibody immunomagnetic bead provided by the invention has excellent erythrocyte separation efficiency.
Owner:ZHEJIANG UNIV BINJIANG RES INST

Chitosan modified gold nanocluster, preparation method and application in red blood cell immobilization

The invention belongs to the technical field of biological medicine, and particularly relates to a chitosan modified gold nanocluster, a preparation method and application in red blood cell immobilization. According to the synthesis method of the CS-GSH-AuNCs cluster, a two-step low-temperature modification method is utilized, GSH-AuNCs core nanoparticles with a definite structure are synthesized firstly, then chitosan is modified through electrostatic interaction, the reaction condition is low temperature and nitrogen protection, the reaction condition is mild, the product repeatability is high, and the original structure of GSH-AuNCs is more complete. Experiments show that the CS-GSH-AuNCs cluster synthesized by the method has good acid and alkali tolerance and temperature tolerance, the effect of immobilizing red blood cells is good, and the biological safety is high.
Owner:TIANJIN DEXIANG BIOTECHNOLOGY CO LTD

Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

PendingUS20250262204A1Heavy metal active ingredientsNervous disorderCongenital erythropoietic porphyriaPharmaceutical drug
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and / or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Owner:DISC MEDICINE INC

Process for providing PEGylated protein composition

Processes for providing a PEGylated protein composition comprising mono-PEGylated protein and oligo-PEGylated protein, and processes for providing mono-PEGylated protein compositions with high yield and productivity are provided. The processes are particularly suitable for providing mono-PEGylated erythropoietin composition. The processes comprise reacting a non-PEGylated protein with a PEGylation reagent to produce a mixture comprising non-PEGylated, mono-PEGylated and oligo-PEGylated protein, subjecting the mixture to a step of anion exchange chromatography, and recycling non-PEGylated protein into further PEGylation reactions.
Owner:F HOFFMANN LA ROCHE INC

H9N2 subtype avian influenza virus virus-like particle vaccine and preparation method thereof

The invention discloses an H9N2 subtype avian influenza virus virus-like particle. The virus-like particle is formed by assembling M1 protein of an H5N1 subtype avian influenza virus and HA protein and NA protein of the H9N2 subtype avian influenza virus; the M1 protein, the HA protein and the NA protein are respectively coded by genes M1, HA and NA, and the genes M1, HA and NA respectively have base sequences shown as SEQ ID NO.1 to SEQ ID NO.3 in a sequence table. Accordingly, the inventor also establishes a corresponding preparation method, i.e., HA, NA and M1 proteins are expressed by using a Bac-to-Bac baculovirus expression system, and the three proteins are self-assembled into the virus-like particles. Researches show that the expressed HA-M1 and NA recombinant protein can be self-assembled in Sf9 cells to form virus-like particles, the concentrated virus-like particles can agglutinate 1% of chicken erythrocytes, and the hemagglutination titer is 1: 64. Therefore, the invention lays a foundation for further research on the virus-like particle vaccine of the H9N2 subtype avian influenza virus.
Owner:GUANGXI VETERINARY RES INST

Establishment of erythroid precursor cell line capable of conditional maturation using gene overexpression

PendingUS20250027045A1Genetically modified cellsVirus peptidesErythroid Precursor CellsErythroid cell
The present invention relates to the establishment of an immortalized erythroid precursor cell line capable of conditional maturation, and more specifically, the present invention provides an erythroid precursor cell for producing an erythrocyte having E6 / E7 and Bcl-xL genes transduced therein, and a preparation method therefor.
Owner:INDUSTRY UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

Destabilized are 3'utrs as therapeutics for cancer

A nucleotide that encodes for a destabilized RNA that codes for ERBB2 (erythroblastic oncogene B) or MYC oncogenes. The destabilization occurs in an adenylate-uridylate rich element (ARE) stabilizing motif. Without wishing to be bound to any particular theory, changing the stabilizing motifs of ERBB2 and MYC to destabilization motifs is believed to lead to the rapid degradation of their transcripts. Thus, in turn, renders the composition useful as a therapeutic for cancer.
Owner:RES FOUND THE CITY UNIV OF NEW YORK +1

Compositions and methods for MED26-mediated regulation of erythrocyte formation

PendingJP2026521879AErythrocyte differentiationMED26
A method for promoting erythrocyte differentiation is provided. A method for increasing RNA polymerase II arrest mediated by the MED26 polypeptide is also provided. Furthermore, a method for delivering reagents to cells is also provided.
Owner:PEKING UNIV +1

An erythrocyte-specific antibody screening test kit and preparation method of this test kit

The invention relates to an erythrocyte specific antibody screening test kit expressing a single antigen from a target erythrocyte (RBC) antigen (RhD and RhCE as 2 different antigens derived from RBC and 45 or more antigens in total including some variants of these two antigens) and a preparation method of this test kit. Said antigens are transgenically produced and provide the clearest results compared to traditional methods of antibody screening. Field-targeted mutation process is applied during the preparation of the erythrocyte-specific antibody screening test kit subject to the invention.
Owner:DİA PRO TIBBİ ÜRÜNLER SANAYİ & TİCARET ANONİM ŞİRKETİ

Construction of engineered erythrocyte extracellular vesicle drug delivery system and application of engineered erythrocyte extracellular vesicle drug delivery system in leukemia

The invention belongs to the technical field of biological medicine, and particularly relates to construction of an engineered erythrocyte extracellular vesicle drug delivery system and application of the engineered erythrocyte extracellular vesicle drug delivery system in leukemia. The invention firstly provides a leukemia cell targeting composite immunomodulator, which is composed of a drug carrying system prepared from erythrocyte extracellular vesicles and a content, the medicine carrying system comprises erythrocyte extracellular vesicles and targeting parts connected to the erythrocyte extracellular vesicles; the content is a small molecule drug and a small interfering RNA (Ribonucleic Acid) synergistic substance. The composite immunomodulator has a composite effect of inducing leukemia cell immunogen cell death and immune activation.
Owner:FULING HOSPITAL AFFILIATED TO CHONGQING UNIV